Jan Mareš

Publications (5)12.44 Total impact

• Article: Tau protein and beta-amyloid1-42 CSF levels in different phenotypes of Parkinson’s disease

  Hana Přikrylová Vranová, Jan Mareš, Petr Hluštík, Martin Nevrlý, David Stejskal, Jana Zapletalová, Radko Obereigneru, Petr Kaňovský
  [show abstract] [hide abstract]
  ABSTRACT: Parkinson’s disease (PD) is a neurodegenerative disorder with highly heterogeneous clinical manifestations. This fact has prompted many attempts to divide PD patients into clinical subgroups. This could lead to a better recognition of pathogenesis, improving targeted treatment and the prognosis of PD patients. The aim of the present study was to obtain cerebrospinal fluid (CSF) samples in PD patients and to search for a relationship between neurodegenerative CSF markers (tau protein, beta-amyloid1-42 and index tau protein/beta-amyloid1-42) and the clinical subtypes. PD patients were divided into three subgroups: early disease onset (EDO), tremor-dominant PD (TD-PD), and non-tremor dominant PD (NT-PD) according to the previously published classification. Neurodegenerative markers in the CSF were assessed in these three groups of patients suffering from PD (EDO-17, TD-15, NT-16 patients) and in a control group (CG) of 19 patients suffering from non-degenerative neurological diseases and 18 patients with Alzheimer’s disease (AD). The NT-PD patients were found to have significantly higher levels of CSF tau protein and index tau/beta than the control subjects and other Parkinsonian subgroups, but no significant differences in these markers were found between AD and NT-PD patients. In the context of more rapid clinical progression and more pronounced neuropathological changes in the NT-PD patient group, our results corroborate the opinion that CSF level of tau protein may be regarded as a potential laboratory marker of the presence and severity of neurodegeneration. KeywordsParkinson’s disease subgroups–Tau protein–Beta-amyloid1-42 –Index tau/beta–CSF
  Acta Neurovegetativa 04/2012; 119(3):353-362. · 2.73 Impact Factor
• Article: CSF markers of neurodegeneration in Parkinson’s disease

  Hana Přikrylová Vranová, Jan Mareš, Martin Nevrlý, David Stejskal, Jana Zapletalová, Petr Hluštík, Petr Kaňovský
  [show abstract] [hide abstract]
  ABSTRACT: Parkinson’s disease (PD) is a chronic, progressive, neurodegenerative disease with a multifactorial etiology. Protein accumulation is speculated by some to play a prominent role in the pathogenesis of PD. The severity of neurodegeneration should correlate with cerebrospinal fluid (CSF) levels of these neurodegenerative markers (NDMs). The aims of the study were to assess the CSF levels of tau protein, beta-amyloid (1–42), cystatin C, and clusterin in patients suffering from PD and in a control group, to compare the CSF levels between the two groups and to correlate them to PD duration. NDMs in the CSF were assessed in 32 patients suffering from PD and in a control group (CG) of 30 patients. The following statistically significant differences in the CSF were found: higher tau protein (p=0.045) and clusterin levels (p=0.004) in PD patients versus CG; higher tau protein levels (p=0.033), tau protein/beta-amyloid (1–42) ratio (p=0.011), and clusterin (p=0.044) in patients suffering from PD for <2years versus patients suffering PD for more than 2years. No differences between beta-amyloid (1–42) and cystatin C CSF levels were found in the CG and PD patients groups. Significantly higher tau protein and clusterin CSF levels in the group of PD patients with disease duration of <2years probably reflect the fact that most neurodegenerative changes in PD patients occur in the initial stage of disease. KeywordsParkinson’s disease-Tau protein-Clusterin-CSF-Neurodegeneration
  Acta Neurovegetativa 04/2012; 117(10):1177-1181. · 2.73 Impact Factor
• Article: Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease.

  Hana Přikrylová Vranová, Jan Mareš, Petr Hluštík, Martin Nevrlý, David Stejskal, Jana Zapletalová, Radko Obereigneru, Petr Kaňovský
  [show abstract] [hide abstract]
  ABSTRACT: Parkinson's disease (PD) is a neurodegenerative disorder with highly heterogeneous clinical manifestations. This fact has prompted many attempts to divide PD patients into clinical subgroups. This could lead to a better recognition of pathogenesis, improving targeted treatment and the prognosis of PD patients. The aim of the present study was to obtain cerebrospinal fluid (CSF) samples in PD patients and to search for a relationship between neurodegenerative CSF markers (tau protein, beta-amyloid(1-42) and index tau protein/beta-amyloid(1-42)) and the clinical subtypes. PD patients were divided into three subgroups: early disease onset (EDO), tremor-dominant PD (TD-PD), and non-tremor dominant PD (NT-PD) according to the previously published classification. Neurodegenerative markers in the CSF were assessed in these three groups of patients suffering from PD (EDO-17, TD-15, NT-16 patients) and in a control group (CG) of 19 patients suffering from non-degenerative neurological diseases and 18 patients with Alzheimer's disease (AD). The NT-PD patients were found to have significantly higher levels of CSF tau protein and index tau/beta than the control subjects and other Parkinsonian subgroups, but no significant differences in these markers were found between AD and NT-PD patients. In the context of more rapid clinical progression and more pronounced neuropathological changes in the NT-PD patient group, our results corroborate the opinion that CSF level of tau protein may be regarded as a potential laboratory marker of the presence and severity of neurodegeneration.
  Acta Neurovegetativa 09/2011; 119(3):353-62. · 2.73 Impact Factor
• Article: Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome.

  Vladimira Sladkova, Jan Mareš, Blanka Lubenova, Jana Zapletalova, David Stejskal, Petr Hlustik, Petr Kanovsky
  [show abstract] [hide abstract]
  ABSTRACT: Literature includes evidence of initial predominance of inflammation and later development of neurodegeneration in the pathogenesis of multiple sclerosis (MS). To search for differences in inflammatory and degenerative cerebrospinal fluid (CSF) markers between relapsing-remitting MS (RRMS) and the clinical isolated syndrome (CIS). A total of 148 subjects were evaluated, 65 MS patients (45 RRMS and 20 CIS) and 83 controls. The evaluated parameters included albumin quotient and prealbumin, transferrin, C3 and C4 complement factors, haptoglobin, beta-2-microglobulin, orosomucoid, alpha-1-antitrypsin, apolipoprotein A-I, apolipoprotein B, cystatin C, neuron-specific enolase, tau protein, beta-amyloid, oligoclonal IgG band (OCB), and IgG quotient (QIgG). No differences were found in the inflammatory and degenerative CSF markers between patients with RRMS and CIS. QIgG was higher in RRMS than that in CIS but the number of OCB was higher after CIS. Cystatin C levels were significantly lower in RRMS compared to the other groups. It can be considered an indicator of the demyelination degree. Normal values of beta-amyloid were less frequent in RRMS compared to those in controls.
  Neurological Research 05/2011; 33(4):415-20. · 1.52 Impact Factor
• Article: CSF markers of neurodegeneration in Parkinson's disease.

  Hana Přikrylová Vranová, Jan Mareš, Martin Nevrlý, David Stejskal, Jana Zapletalová, Petr Hluštík, Petr Kaňovský
  [show abstract] [hide abstract]
  ABSTRACT: Parkinson's disease (PD) is a chronic, progressive, neurodegenerative disease with a multifactorial etiology. Protein accumulation is speculated by some to play a prominent role in the pathogenesis of PD. The severity of neurodegeneration should correlate with cerebrospinal fluid (CSF) levels of these neurodegenerative markers (NDMs). The aims of the study were to assess the CSF levels of tau protein, beta-amyloid (1-42), cystatin C, and clusterin in patients suffering from PD and in a control group, to compare the CSF levels between the two groups and to correlate them to PD duration. NDMs in the CSF were assessed in 32 patients suffering from PD and in a control group (CG) of 30 patients. The following statistically significant differences in the CSF were found: higher tau protein (p = 0.045) and clusterin levels (p = 0.004) in PD patients versus CG; higher tau protein levels (p = 0.033), tau protein/beta-amyloid (1-42) ratio (p = 0.011), and clusterin (p = 0.044) in patients suffering from PD for <2 years versus patients suffering PD for more than 2 years. No differences between beta-amyloid (1-42) and cystatin C CSF levels were found in the CG and PD patients groups. Significantly higher tau protein and clusterin CSF levels in the group of PD patients with disease duration of <2 years probably reflect the fact that most neurodegenerative changes in PD patients occur in the initial stage of disease.
  Acta Neurovegetativa 10/2010; 117(10):1177-81. · 2.73 Impact Factor